- 7 million people are living with HIV, 40% don’t know their status
- New HIV infections among children have declined by 50% since 2010.
- The incidence of HIV/AIDS is increasing among young gay men.
- UNAIDS released a report showing 18.2 million people are now on antiretroviral therapy. However, it found women aged between 15 and 24 were at great risk.
- The number of people living with HIV on antiretroviral therapy has increased by about a third, 3 million more than the 15 million by 2014.
- In high income countries, 31% of people living with HIV are now over the age of 50 due to antiretroviral therapy.
- Recent updated UNAIDS estimates indicate that US$ 26.2 billion will be required for the AIDS response in 2020, with US$ 23.9 billion required in 2030.
- Brazil represents the largest number of people living with HIV in Latin America at 47%. Worldwide, it is one of 15 countries which represent 75% of the global number of people living with HIV.
- Western and central Africa are current areas of concern – they account for 18% of people living with HIV. Lack of treatment access means the area also accounts for 30% of all Aids-related deaths globally
- In June 2016, GSK made a groundbreaking deal to make the HIV drug Tivicay available for Botswana’s national effort to test and treat as many citizens as possible.
- Cipla offers free antiretroviral technology to any African nation looking to produce their own drugs. In 2001, India’s Cipla had introduced the world’s first 3-in-1 fixed dose combination (Stavudine, Lamivudine, and Nevirapine). Now, a third of people living with HIV in 115 countries are taking this drug.
- Gilead Sciences Inc. has begun marketing its HIV treatment Truvada to prevent infection with the virus that causes AIDS.
- Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Global Top Players in Intraocular Lens (IOL) Market
- Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment
- How are Nanobots Proving Their Excellence in the Healthcare Industry?
- Top 10 Expected Oncology Drug Launches in 2023
On World AIDS Day…
Dec 01, 2016 | Reading Time: < 1 minutes
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC
FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...Find More
Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
Clinical Diagnosis (Dx) is the identification and confirmation of disease or disorder or exposure to xenobiotics to explain the clinical manifestations shown by the patient. It is also performed to assess the state of health of an individual (routine health checkup), functioning of any organ or associated metabolic...Find More
EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib
EU Regulator Starts its Review of Cidara Therapeutics’ Candidiasis Therapy Rezafungin The EU regulator has begun its review of Cidara Therapeutics’ once-weekly antifungal rezafungin, with a decision expected next year as a new option for serious, invasive candida infections. The application is based on the ReSTO...Find More
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.